AttendMe Owl Logo
AttendMe
Sign In
All Pathways
CardiologyManagement

Atrial Fibrillation Management (ESC 2024 AF-CARE)

Atrial Fibrillation Management (ESC 2024 AF-CARE): New-Onset AFib Detected → [C] Comorbidities & Risk Factors → [A] Stroke Risk Assessment → Score ≥2: A...

Pathway Overview

12 steps

Algorithm Steps

12 total

  1. 01Start

    New-Onset AFib Detected

    Patient presents with atrial fibrillation

  2. 02Action

    [C] Comorbidities & Risk Factors

    Address modifiable risk factors

    • Hypertension management
    • Obesity/weight loss
    • Diabetes control
    • Sleep apnea treatment (CPAP)
    • Alcohol reduction
    • Exercise program
  3. 03Decision

    [A] Stroke Risk Assessment

    Calculate CHA₂DS₂-VA Score

    • C: Congestive HF (+1)
    • H: Hypertension (+1)
    • A₂: Age ≥75 (+2)
    • D: Diabetes (+1)
    • S₂: Stroke/TIA/TE (+2)
    • V: Vascular disease (+1)
    • A: Age 65-74 (+1)
    • Note: Sex removed in ESC 2024
  4. 04Action

    Score ≥2: Anticoagulate

    Oral anticoagulation recommended (Class I)

    • DOAC preferred over warfarin
    • Apixaban, Rivaroxaban, Edoxaban, or Dabigatran
    • Check renal function for dosing
  5. 05Decision

    [R] Symptom Management

    Rate vs Rhythm Control Strategy

    • Assess symptom burden (EHRA score)
    • Consider patient preference
    • Age and activity level
  6. 06Action

    Rate Control

    Target HR <110 bpm at rest (lenient)

    • Beta-blocker (bisoprolol, metoprolol)
    • Diltiazem/Verapamil (if no HFrEF)
    • Digoxin (adjunct, not monotherapy)
    • Stricter control (<80) if persistent symptoms
  7. 07Action

    [E] Evaluate & Reassess

    Ongoing monitoring and adjustment

    • Regular follow-up (3-6 months)
    • Symptom assessment (EHRA score)
    • Check therapy adherence
    • Renal function monitoring (DOAC dosing)
    • Adjust strategy as needed
  8. 08Outcome

    AFib Controlled

    Symptoms managed, stroke risk addressed

  9. 09Warning

    Consider Specialist Referral

    Complex cases, refractory symptoms, ablation candidate

  10. 10Action

    Rhythm Control

    Preferred for younger, symptomatic patients

    • Cardioversion (electrical or pharmacological)
    • Antiarrhythmic drugs (Class I, III)
    • Catheter ablation (Class I for symptom control)
    • Consider early rhythm control (EAST-AFNET 4)
  11. Path rejoins step 07Shared downstream outcome
  12. 11Action

    Score 1: Consider OAC

    Shared decision-making (Class IIa)

    • Discuss bleeding vs stroke risk
    • Use HAS-BLED to identify modifiable risks
    • Do NOT withhold OAC due to bleeding risk
  13. Path rejoins step 05Shared downstream outcome
  14. 12Action

    Score 0: No OAC

    Anticoagulation not recommended

    • Reassess if risk factors develop
    • Annual stroke risk <1%
  15. Path rejoins step 05Shared downstream outcome

Guideline Source

2024 ESC Guidelines for the Management of Atrial Fibrillation

DOI: 10.1093/eurheartj/ehae176View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Does not address pediatric AFib
  • Simplified for common presentations - complex patients require specialist input
  • Drug dosing not included - refer to institutional protocols
  • Does not cover valvular AFib (mechanical valve, moderate-severe MS)

Contraindicated Populations

pediatricpregnancyvalvular_afib

Applicable Regions

EUUS

EU: Uses CHA₂DS₂-VA score per ESC 2024 (sex removed as modifier)

US: ACC/AHA 2023 uses CHA₂DS₂-VASc - consider local practice

Version 1Next review: 2028-09-01

Related Cardiology Pathways

ACLS Bradycardia Algorithm (AHA 2025)

Emergency

ACLS Tachycardia with Pulse Algorithm (AHA 2025)

Emergency

AFib Anticoagulation Decision (ESC 2024)

Management

Aortic Stenosis Management (ESC/EACTS 2025)

Management

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

CHA₂DS₂-VASc Score

Stroke risk stratification in atrial fibrillation

Open page

Compare

AttendMe.ai vs UpToDate

See how this pathway workflow compares against UpToDate.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Atrial Fibrillation Management (ESC 2024 AF-CARE)?

The Atrial Fibrillation Management (ESC 2024 AF-CARE) is a management clinical algorithm for Cardiology. It provides a structured decision tree to guide clinical decision-making, based on 2024 ESC Guidelines for the Management of Atrial Fibrillation.

What guideline is the Atrial Fibrillation Management (ESC 2024 AF-CARE) based on?

This algorithm is based on 2024 ESC Guidelines for the Management of Atrial Fibrillation (DOI: 10.1093/eurheartj/ehae176).

What are the limitations of the Atrial Fibrillation Management (ESC 2024 AF-CARE)?

Known limitations include: Does not address pediatric AFib; Simplified for common presentations - complex patients require specialist input; Drug dosing not included - refer to institutional protocols; Does not cover valvular AFib (mechanical valve, moderate-severe MS). Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Atrial Fibrillation Management (ESC 2024 AF-CARE) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free